Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-09T19:43:43.395Z Has data issue: false hasContentIssue false

68 - Guanfacine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Tenex, Intuniv

Generic?

• Yes

Class

• α2-adrenergic agonist

Commonly Prescribed for

(FDA approved in bold)

Attention deficit hyperactivity disorder (ADHD)

Hypertension

• Gilles de la Tourette syndrome (GTS)

• Tics

• Neuropathic pain

• Opioid detoxification

• Alcohol withdrawal

• Hypertensive “urgency”

• Post-traumatic stress disorder

How the Drug Works

• A centrally acting α2A-adrenergic agonist. Reduces sympathetic output from CNS, which decreases cardiac output, peripheral vascular resistance, and blood pressure

• Specifically targets α2A receptors in the brainstem vasomotor center, decreasing presynaptic calcium levels and the release of norepinephrine

How Long Until It Works

• ADHD: after 1 week

• Hypertension, withdrawal: less than 2 hours

• GTS: weeks to months

If It Works

• In neurological disorders, such as tics, continue to assess effect of the medication to see if it is still needed

If It Doesn't Work

• GTS/tics: neuroleptics are often effective, but their use should be reserved for patients with significant social isolation or embarrassment

Best Augmenting Combos for Partial Response or Treatment-Resistance

• In hypertension, combine with treatments less likely to cause orthostasis (ACE inhibitors, diuretics)

• Tics and GTS symptoms may change over time. Many patients improve with age. Behavioral and psychological therapies are useful and education and reassurance are all that is needed in mild cases

• Indentify and treat comorbid conditions such as ADHD or obsessive-compulsive disorder

Tests

• Monitor blood pressure and pulse

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Related to α2A-adrenergic agonist effect – hypotension and sedation

Notable AEs

• Dry mouth, drowsiness, dizziness, constipation, weakness, headache, depression, paresthesia, dermatitis, impotence, and syncope

Life-Threatening or Dangerous AEs

• Hypotension, bradycardia, and syncope

• Rapid withdrawal can cause rebound hypertension with increased catecholamine levels

Weight Gain

• Unusual

Sedation

• Common

What to Do About AEs

• Lower the dose and take the highest dose in the evening. Many AEs (especially sedation) decrease with time

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 250 - 253
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Guanfacine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.069
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Guanfacine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.069
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Guanfacine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.069
Available formats
×